FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000438429> ?p ?o ?g. }

• W2000438429 endingPage "5225" @default.
• W2000438429 startingPage "5219" @default.
• W2000438429 abstract "BACKGROUND: Adult “translocation” renal cell carcinoma (RCC), bearing transcription factor E3 (TFE3) gene fusions at Xp11.2, is a recently recognized, unique entity for which prognosis and therapy remain poorly understood. In the current study, the authors investigated the effect of vascular endothelial growth factor (VEGF)-targeted therapy in this distinct subtype of RCC. METHODS: A retrospective review was conducted to describe the clinical characteristics and outcome of adult patients with metastatic Xp11.2 RCC who had strong TFE3 nuclear immunostaining and received anti-VEGF therapy. Tumor response to anti-VEGF therapy was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS) distributions. RESULTS: Fifteen patients were identified, of whom 10, 3, and 2 received sunitinib, sorafenib, and monoclonal anti-VEGF antibodies, respectively. The median follow-up was 19.1 months, the median age of the patients was 41 years, and the female:male ratio was 4:1. Initial histologic description included clear cell (n = 8 patients), papillary (n = 1 patient), or mixed clear cell/papillary RCC (n = 6 patients). Five patients had received prior systemic therapy. Five patients had undergone fluorescent in situ hybridization analysis and all demonstrated a translocation involving chromosome Xp11.2. When treated with VEGF-targeted therapy, 3 patients achieved a partial response, 7 patients had stable disease, and 5 patients developed progressive disease. The median PFS and OS of the entire cohort were 7.1 months and 14.3 months, respectively. CONCLUSIONS: Adult-onset, translocation-associated metastatic RCC is an aggressive disease that affects a younger population of patients with a female predominance. In the current study, VEGF-targeted agents appeared to demonstrate some efficacy. Cancer 2010. © 2010 American Cancer Society." @default.
• W2000438429 created "2016-06-24" @default.
• W2000438429 creator A5007052233 @default.
• W2000438429 creator A5007689146 @default.
• W2000438429 creator A5027134730 @default.
• W2000438429 creator A5048322604 @default.
• W2000438429 creator A5052504518 @default.
• W2000438429 creator A5054206895 @default.
• W2000438429 creator A5058115259 @default.
• W2000438429 creator A5062740919 @default.
• W2000438429 creator A5067620976 @default.
• W2000438429 creator A5073593424 @default.
• W2000438429 creator A5089628178 @default.
• W2000438429 date "2010-07-21" @default.
• W2000438429 modified "2023-10-16" @default.
• W2000438429 title "Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma" @default.
• W2000438429 cites W1982596186 @default.
• W2000438429 cites W1986087564 @default.
• W2000438429 cites W2000491157 @default.
• W2000438429 cites W2004511237 @default.
• W2000438429 cites W2020185242 @default.
• W2000438429 cites W2033162609 @default.
• W2000438429 cites W2036394847 @default.
• W2000438429 cites W2060512760 @default.
• W2000438429 cites W2070141596 @default.
• W2000438429 cites W2072997207 @default.
• W2000438429 cites W2097094046 @default.
• W2000438429 cites W2099752220 @default.
• W2000438429 cites W2101995865 @default.
• W2000438429 cites W2113780775 @default.
• W2000438429 cites W2133908084 @default.
• W2000438429 cites W2139248078 @default.
• W2000438429 cites W2143782771 @default.
• W2000438429 cites W2154862138 @default.
• W2000438429 cites W2155680858 @default.
• W2000438429 cites W2160120519 @default.
• W2000438429 cites W2161797239 @default.
• W2000438429 cites W2169500410 @default.
• W2000438429 cites W2330018939 @default.
• W2000438429 cites W4229808435 @default.
• W2000438429 cites W4293241248 @default.
• W2000438429 doi "https://doi.org/10.1002/cncr.25512" @default.
• W2000438429 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4667556" @default.
• W2000438429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20665500" @default.
• W2000438429 hasPublicationYear "2010" @default.
• W2000438429 type Work @default.
• W2000438429 sameAs 2000438429 @default.
• W2000438429 citedByCount "121" @default.
• W2000438429 countsByYear W20004384292012 @default.
• W2000438429 countsByYear W20004384292013 @default.
• W2000438429 countsByYear W20004384292014 @default.
• W2000438429 countsByYear W20004384292015 @default.
• W2000438429 countsByYear W20004384292016 @default.
• W2000438429 countsByYear W20004384292017 @default.
• W2000438429 countsByYear W20004384292018 @default.
• W2000438429 countsByYear W20004384292019 @default.
• W2000438429 countsByYear W20004384292020 @default.
• W2000438429 countsByYear W20004384292021 @default.
• W2000438429 countsByYear W20004384292022 @default.
• W2000438429 countsByYear W20004384292023 @default.
• W2000438429 crossrefType "journal-article" @default.
• W2000438429 hasAuthorship W2000438429A5007052233 @default.
• W2000438429 hasAuthorship W2000438429A5007689146 @default.
• W2000438429 hasAuthorship W2000438429A5027134730 @default.
• W2000438429 hasAuthorship W2000438429A5048322604 @default.
• W2000438429 hasAuthorship W2000438429A5052504518 @default.
• W2000438429 hasAuthorship W2000438429A5054206895 @default.
• W2000438429 hasAuthorship W2000438429A5058115259 @default.
• W2000438429 hasAuthorship W2000438429A5062740919 @default.
• W2000438429 hasAuthorship W2000438429A5067620976 @default.
• W2000438429 hasAuthorship W2000438429A5073593424 @default.
• W2000438429 hasAuthorship W2000438429A5089628178 @default.
• W2000438429 hasBestOaLocation W20004384291 @default.
• W2000438429 hasConcept C121608353 @default.
• W2000438429 hasConcept C126322002 @default.
• W2000438429 hasConcept C142724271 @default.
• W2000438429 hasConcept C143998085 @default.
• W2000438429 hasConcept C167734588 @default.
• W2000438429 hasConcept C2776694085 @default.
• W2000438429 hasConcept C2777025900 @default.
• W2000438429 hasConcept C2777472916 @default.
• W2000438429 hasConcept C2778019345 @default.
• W2000438429 hasConcept C2778695046 @default.
• W2000438429 hasConcept C2778822529 @default.
• W2000438429 hasConcept C2779490328 @default.
• W2000438429 hasConcept C2779984678 @default.
• W2000438429 hasConcept C2781230642 @default.
• W2000438429 hasConcept C2781278892 @default.
• W2000438429 hasConcept C71924100 @default.
• W2000438429 hasConceptScore W2000438429C121608353 @default.
• W2000438429 hasConceptScore W2000438429C126322002 @default.
• W2000438429 hasConceptScore W2000438429C142724271 @default.
• W2000438429 hasConceptScore W2000438429C143998085 @default.
• W2000438429 hasConceptScore W2000438429C167734588 @default.
• W2000438429 hasConceptScore W2000438429C2776694085 @default.
• W2000438429 hasConceptScore W2000438429C2777025900 @default.
• W2000438429 hasConceptScore W2000438429C2777472916 @default.
• W2000438429 hasConceptScore W2000438429C2778019345 @default.

• next